Samsung Biologics , a leading contract development and manufacturing organization, announced strong financial results for the secondquarter of fiscal 2021. John Rim, CEO of Samsung Biologics, stated, “The second-quarter financial performance demonstrates our ability to maintain steady operations despite the global supply disruptions brought on by the pandemic and our commitment to delivering life-saving treatments […]

The post Samsung Biologics Reports Strong SecondQuarter 2021 Financial Results first appeared on World Pharma Today.